Related Experiment Video

Updated: Feb 2, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents

María Luisa Gutiérrez García1, María Luisa Manzano Alonso2, Juan Ángel Ferrer Rosique3

  • 1Digestivo, HUFA, España.

Revista Espanola De Enfermedades Digestivas
|November 14, 2018
PubMed

Insights

Hepatitis B virus (HBV) reactivation is common but not clinically relevant in hepatitis C virus (HCV) patients treated with direct-acting antivirals (DAAs). HBV screening rates are high in this population.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) has raised concerns about potential hepatitis B virus (HBV) reactivation.
  • Understanding HBV/HCV coinfection and reactivation is crucial for patient management during DAA therapy.

Purpose of the Study:

  • To determine the prevalence of HBV/HCV coinfection and the incidence/clinical relevance of HBV reactivation in HCV patients treated with DAAs in Madrid.
  • To assess HBV screening rates among HCV patients in the region.

Main Methods:

  • A cohort of 1,337 HCV patients treated with DAAs between January 2015 and June 2017 in South Madrid was analyzed.
  • Prevalence of HBsAg positivity and previous HBV infection markers were recorded.
  • Incidence and clinical significance of HBV reactivation were monitored.

Main Results:

  • The prevalence of HBsAg positive HBV infection was low (0.67%).
  • Virological HBV reactivation occurred in 50% of HBsAg positive patients without prior treatment, but without biochemical relevance.
  • Patients with previous HBV infection markers showed normal transaminases throughout treatment and follow-up.
  • The HBV screening rate reached 92.9%.

Conclusions:

  • HBV prevalence is low in HCV patients in the studied area of Madrid.
  • HBV reactivation in HBsAg positive patients on DAAs is frequent but clinically insignificant.
  • High HBV screening rates are observed in HCV patients eligible for DAA treatment in this region.
Abstract

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

14.1K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
280
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
244
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
581
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
309
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K